CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Appraise the efficacy and safety of approved and investigational ALK inhibitors, and determine how these agents can be integrated into the protocol and nonresearch care of patients with NSCLC with ALK rearrangements.
  • Describe mechanisms of tumor resistance to ALK inhibitors, and discern how available and investigational therapies can be optimally employed in current and future clinical practice for patients with advanced NSCLC with ALK rearrangements.
  • Consider the mechanism of action of, available data with and FDA approval of entrectinib for patients with NSCLC with ROS1 alterations, and discern how this agent can be appropriately and safely integrated into routine clinical care.
  • Develop an optimal approach to the management of NSCLC in patients with ALK or ROS1 rearrangements and CNS metastases, considering the implications of symptomatology, number of lesions and other factors.
  • Recall ongoing clinical trials evaluating novel therapeutic approaches for NSCLC with ALK or ROS1 rearrangements, and refer appropriate patients for participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and his spouse/partner) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  D Ross Camidge, MD, PhD
  Professor of Medicine/Oncology
  Joyce Zeff Chair in Lung Cancer Research
  Director of Thoracic Oncology
  University of Colorado, Anschutz Medical Campus
  Denver, Colorado
  
  Company Sponsored Trials at Institution (PI Roles): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Hansoh Pharma, Inhibrx, Karyopharm Therapeutics, Lycera, Merck, Pfizer Inc, Phosplatin Therapeutics, PsiOxus Therapeutics, Rain Therapeutics, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Symphogen A/S, Takeda Oncology; Data Safety Monitoring Board: AstraZeneca Pharmaceuticals LP, HiberCell; ILD Adjudication Committee: Bristol-Myers Squibb Company, Daiichi Sankyo Inc; Scientific Advisory Board: Amgen Inc, Anchiano Therapeutics, GlaxoSmithKline, Helsinn Healthcare SA, Janssen Biotech Inc, Lilly, OnKure, Pfizer Inc, Qilu Pharmaceutical Co Ltd, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Takeda Oncology; Scientific Review Committee: Apollomics Inc, EMD Serono Inc, Sunovion Respiratory Development Inc.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Takeda Oncology.
  
  Release date: November 2020
  Expiration date: November 2021